Benzinga | Mar 9, 2021 09:18AM EST

Cellectar Reports Was Granted Japanese Composition Of Matter Patent For Its Phospholipid-Ether Drug Conjugates

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Japan Patent Office (JPO) has granted patent number 6832861, titled, "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles." The patent provides composition of matter and use protection for the company's proprietary phospholipid-ether (PLE), targeted delivery vehicle analogs in combination with a broad range of commonly used chemotherapeutic classes such as alkaloids, nucleoside analogs, as well as other classes of small molecule chemotherapeutic agents.

"This patent represents an important part of Cellectar's expanding intellectual property portfolio as the company continues to generate value from R&D and expansion of its PDC franchise," said James Caruso, president and CEO of Cellectar. "Our expanded portfolio now provides intellectual property protection for our small molecule franchise in the major global markets of the U.S., Europe and Japan."

The cancer-targeting PLE delivery vehicle serves as the foundation for the company's research, development and pipeline including lead product candidate CLR 131, which continues to advance through clinical studies in both adult and pediatric cancer indications.